Abstract:
The first part of the webinar talk will present the principles of analytical methods currently employed for serum concentrations of therapeutic antibodies, and why they are subject to a dedicated working group in the ENOTTA COST action.The second part of this webinar presents the experience on the implementation of therapeutic drug monitoring and model-informed precision dosing (MIPD) of biologics in inflammatory bowel disease at the Bellvitge University Hospital.
Dr Núria Padullés Zamora, Bellvitge University Hospital, Barcelona (Spain)
Dr Núria Padullés is a Hospital Pharmacist at the Bellvitge University Hospital in Barcelona (Spain) and Assistant Professor at the Dept. of Pharmacy and Pharmaceutical Technology and Physical Chemistry at the Faculty of Pharmacy, Barcelona University. She leads the Pharmacotherapy, Pharmacogenetics and Pharmaceutical Technology research group (Translational Medicine Area) at the Bellvitge Biomedical Research Institute (IDIBELL). Her research is focused on optimizing therapeutic antibodies dosing in immune-mediated inflammatory diseases.
Contact: npadulles@bellvitgehospital.cat
Prof. Silje Skrede, University of Bergen, Norway
Silje Skrede is professor of pharmacology and head of innovation at the Department of Clinical Science, Faculty of Medicine, University of Bergen, senior consultant in clinical pharmacology at Haukeland University Hospital, Bergen, Norway and group leader, Mohn Research Centre for Psychotic Disorders. Main research interests include molecular mechanisms of antipsychotic-induced metabolis adverse effects as well as therapeutic drug monitoring of biologic drugs, with particular focus on the impact analytics.